Association of human leukocyte antigen class II alleles with response to immunosuppressive therapy in Korean aplastic anemia patients

Human Immunology

Volumn 71, Issue 1, 2010, Pages 88-92

  Song, Eun Young ^a   Kang, Hyoung Jin ^a   Shin, Hee Young ^a   Ahn, Hyo Seop ^a   Kim, Inho ^a   Yoon, Sung Soo ^a   Park, Seonyang ^a   Kim, Byoung Kook ^a   Park, Myoung Hee ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Aplastic anemia; Cyclosporine; HLA DQ; HLA DR; Immunosuppressive therapy

Indexed keywords

CYCLOSPORIN A; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; HLA DR15 ANTIGEN; HLA DR4 ANTIGEN; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY;

ADULT; APLASTIC ANEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KOREA; MALE; PHARMACOGENETICS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ALLELES; ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; HLA-D ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 71249157660     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.10.002     Document Type: Article

References (24)

1. Brodsky R.A., and Jones R.J. Aplastic anemia. Lancet 365 (2005) 1647-1656
2. Young N.S., Calado R.T., and Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 108 (2006) 2509-2519
3. Nakao S., Yamaguchi M., Saito M., Yasue S., Shiobara S., Matsuda T., et al. HLA-DR2 predicts a favorable response to cyclosporine therapy in patients with bone marrow failure. Am J Hematol 40 (1992) 239-240
4. Nimer S.D., Ireland P., Meshkinpour A., and Frane M. An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood 84 (1994) 923-927
5. Nakao S., Takami A., Sugimori N., Ueda M., Shiobara S., Matsuda T., et al. Response to immunosuppressive therapy and an HLA DRB1 allele in patients with aplastic anemia: HLA-DRB1*1501 does not predict response to antithymocyte globulin. Br J Haematol 82 (1996) 155-158
6. Ihan O., Beksac M., Arslan O., Ozcan M., Koc H., Akan H., et al. HLA DR2: a predictive marker in response to cyclosporine therapy in aplastic anemia. Int J Hematol 66 (1997) 291-295
7. Kapustin S.I., Popova T.I., Lyshchov A.A., Imyanitov E.N., Blinov M.N., and Abdulkadyrov K.M. HLA-DR4-Ala74β is associated with risk and poor outcome of severe aplastic anemia. Ann Hematol 80 (2001) 66-71
8. Oguz F.S., Yalman N., Diler A.S., Oguz R., Anak S., and Dorak M.T. HLA-DRB1*15 and pediatric aplastic anemia. Haematologica 87 (2002) 772-774
9. Saunthararajah Y., Nakamura R., Nam J.M., Robyn J., Loberiza F., Maciejewski J.P., et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100 (2002) 1570-1574
10. Usman M., Adil S.N., Moatter T., Bilwani F., Arian S., and Khurshid M. Increased expression of HLA DR2 in acquired aplastic anemia and its impact on response to immunosuppressive therapy. J Pak Med Assoc 54 (2004) 251-254
11. Sugimori C., Yamazaki H., Feng X., Mochizuki K., Konodo Y., Takami A., et al. Roles of DRB1*1501 and DRB1*1502 in the pathogenesis of aplastic anemia. Exp Hematol 35 (2007) 13-20
12. Song E.Y., Park S., Lee D.S., Cho H.I., and Park M.H. Association of human leukocyte antigen-DRB1 alleles with disease susceptibility and severity of aplastic anemia in Korean patients. Hum Immunol 69 (2008) 354-359
13. Nakao S., Takamatsu H., Chuhjo T., Ueda M., Shiobara S., Matsuda T., et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood 84 (1994) 4257-4261
14. Song E.Y., Park H., Roh E.Y., and Park M.H. HLA-DRB1 and -DRB3 allele frequencies and haplotypic associations in Koreans. Hum Immunol 65 (2004) 270-276
15. Song E.Y., Park M.H., Kang S.J., Park H.J., Kim B.C., Tokunaga K., et al. HLA class II allele and haplotype frequencies in Koreans based on 107 families. Tissue Antigens 59 (2002) 475-486
16. Incidence of aplastic anemia: the relevance of diagnostic criteria. By the International Agranulocytosis and Aplastic Anemia study. Blood 70 (1987) 1718-1721
17. Camitta B.M., Thomas E.D., Nathan D.G., Gale R.P., Kopecky K.J., Rappeport J.M., et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood 53 (1979) 504-514
18. Bacigalupo A., Broccia G., Corda G., Arcese W., Carotenuto M., Gallamini A., et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood 85 (1995) 1348-1353
19. Champlin R., Ho W., and Gale R.P. Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N Engl J Med 308 (1983) 113-118
20. Vince A., Poljak M., and Seme K. DNA extraction from archival giemsa-stained bone-marrow slides: comparison of six rapid methods. Br J Haematol 101 (1998) 349-351
21. Park M.H., Whang D.H., and Kang S.J. High resolution HLA-DQB1 typing by combination of PCR-RFLP and PCR-SSCP. Hum Immunol 60 (1999) 901-907
22. Nakao S., Takami A., Takamatsu H., Zeng W., Sugimori N., Yamazaki H., et al. Isolation of a T-cell clone showing HLA-DRB1*0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Blood 89 (1997) 3691-3699
23. Zlabinger G.J., Kudlacek S., Pohanka E., Franz M., Hamilton G., Rosenmayr A., et al. Evidence that sensitivity to cyclosporine is influenced by the HLA-DR phenotype of kidney graft recipients. Transplantation 53 (1992) 758-762
24. Battiwalla M., Hahn T., Radovic M., Roy H., Wahab A., Duman E., et al. Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence. Blood 107 (2006) 1970-1973